Orphagen Pharmaceuticals

Orphagen Pharmaceuticals is a biotech company focused on discovering and developing small molecule ligands that modulate orphan nuclear receptors. They are currently developing OR-812, a novel oral therapeutic for inflammatory bowel disease (IBD), targeting the retinoic acid receptor alpha (RARα). Their work is based on an agnostic approach, exploring proprietary lead molecules with potential in autoimmune disease and oncology.

Buy Funded Startups lists

Funding Round: Grant

Funding Amount: $1.7M

Date: 09-Dec-2024

Investors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Markets: Biotechnology, Pharmaceuticals, Healthtech, Medical

HQ: San Diego, California, United States

Founded: 2001

Website: https://www.orphagen.com/

LinkedIn: https://www.linkedin.com/company/orphagenpharmaceuticals

Twitter:

Instagram: